Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

MLA

Colombo, Nicoletta, et al. “Atezolizumab and Chemotherapy for Advanced or Recurrent Endometrial Cancer (AtTEnd): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology, vol. 25, no. 9, Sept. 2024, pp. 1135–46. EBSCOhost, https://doi.org/10.1016/S1470-2045(24)00334-6.

APA

Colombo, N., Biagioli, E., Harano, K., Galli, F., Hudson, E., Antill, Y., Choi, C. H., Rabaglio, M., Marmé, F., Marth, C., Parma, G., Fariñas-Madrid, L., Nishio, S., Allan, K., Lee, Y. C., Piovano, E., Pardo, B., Nakagawa, S., McQueen, J., … Barretina Ginesta, M. P. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 25(9), 1135–1146. https://doi.org/10.1016/S1470-2045(24)00334-6

Chicago

Colombo, Nicoletta, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, et al. 2024. “Atezolizumab and Chemotherapy for Advanced or Recurrent Endometrial Cancer (AtTEnd): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology 25 (9): 1135–46. doi:10.1016/S1470-2045(24)00334-6.